- Home
- DXR vs OMIC Comparison
DXR vs OMIC Comparison
Compare DXR & OMIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- OMIC
- Stock Information
- Founded
- DXR 1970
- OMIC 2016
- Country
- DXR United States
- OMIC United States
- Employees
- DXR N/A
- OMIC N/A
- Industry
- DXR Medical/Dental Instruments
- OMIC Medical/Dental Instruments
- Sector
- DXR Health Care
- OMIC Health Care
- Exchange
- DXR Nasdaq
- OMIC Nasdaq
- Market Cap
- DXR 42.6M
- OMIC 34.9M
- IPO Year
- DXR N/A
- OMIC 2021
- Fundamental
- Price
- DXR $9.28
- OMIC $21.92
- Analyst Decision
- DXR Strong Buy
- OMIC Hold
- Analyst Count
- DXR 1
- OMIC 2
- Target Price
- DXR $24.75
- OMIC $10.75
- AVG Volume (30 Days)
- DXR 21.7K
- OMIC 34.7K
- Earning Date
- DXR 01-01-0001
- OMIC 11-12-2024
- Dividend Yield
- DXR N/A
- OMIC N/A
- EPS Growth
- DXR N/A
- OMIC N/A
- EPS
- DXR 0.35
- OMIC N/A
- Revenue
- DXR $154,205.00
- OMIC $2,667,000.00
- Revenue This Year
- DXR N/A
- OMIC $10.41
- Revenue Next Year
- DXR N/A
- OMIC $222.15
- P/E Ratio
- DXR $25.91
- OMIC N/A
- Revenue Growth
- DXR N/A
- OMIC 2.77
- 52 Week Low
- DXR $7.11
- OMIC $5.34
- 52 Week High
- DXR $10.04
- OMIC $23.41
- Technical
- Relative Strength Index (RSI)
- DXR 47.02
- OMIC 62.31
- Support Level
- DXR $8.76
- OMIC $21.03
- Resistance Level
- DXR $9.72
- OMIC $22.14
- Average True Range (ATR)
- DXR 0.52
- OMIC 0.76
- MACD
- DXR -0.03
- OMIC -0.22
- Stochastic Oscillator
- DXR 21.74
- OMIC 15.55
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About OMIC Singular Genomics Systems Inc.
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.